afm24
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2020 (NCT04259450)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EGFR inhibitor
FCGR3A inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05109442 | Phase 1/Phase 2 (Phase 2) | Nov 19, 2021 | Affimed GmbH |
| NCT05099549 | Phase 1/Phase 2 (Phase 2) | Nov 3, 2021 | Affimed GmbH, NKGen Biotech, Inc. |
| NCT04259450 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2020 | Affimed GmbH |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affimed GmbH | For profit | 3 | 2 | 1 | 2020 |
| NKGen Biotech, Inc. | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1